98%
921
2 minutes
20
B-vitamin deficiency is common in ageing populations either due to altered dietary habits or altered digestive and metabolic functions. There is limited data on the acute circulating concentrations of B-vitamins and their various forms (vitamers), following ingestion of realistic meals. This study compared the acute circulating B-vitamin and vitamer responses to either an energy-dense (ED) or a nutrient-dense (ND) breakfast meal, consumed in a randomized cross-over sequence, in older and younger adults ( = 15 and 15, aged 67.3 ± 1.5 and 22.7 ± 0.5 years (mean ± SEM), respectively). Eleven differing B-vitamins and vitamers were determined in plasma samples by ultra-high-performance liquid chromatography-tandem mass spectrometry, in the fasting and postprandial state (hourly for 5 h). While postprandial thiamine concentration increased following both meals, riboflavin increased only following a ND meal in both age groups. Many vitamins including nicotinic acid, pantothenic acid, pyridoxal, pyridoxamine, pyridoxal-5'phosphate, and 4-pyridoxic acid remained unaltered, and flavin mononucleotide (FMN), nicotinamide and nicotinuric acid concentrations reduced following both meals. Biological age and food composition had minimal impact on postprandial B-vitamin concentrations, yet the differences between the ED and ND meals for riboflavin highlight the importance of riboflavin intake to achieve adequacy.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6950174 | PMC |
http://dx.doi.org/10.3390/nu11122893 | DOI Listing |
BMJ Open
August 2025
Department of Medical Oncology, Montpellier Cancer Institute, Montpellier, France.
Introduction: Pancreatic adenocarcinoma is a major public health concern due to its high metastatic potential and poor prognosis. However, treatment options remain limited. A promising therapeutic strategy involves the sequential administration of standard therapies.
View Article and Find Full Text PDFAsian Pac J Cancer Prev
July 2025
Department of Pathology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India.
Background: Gastric cancer represents a significant global health concern with poor prognosis and limited early detection methods. Circulating tumor cells (CTCs) that express folate receptors (FRs) have emerged as promising biomarkers for cancer monitoring, as folate receptor-alpha is overexpressed in cancer tissues while remaining absent in normal cells.
Objective: This study aimed to develop and optimize a Folate-Ligand Targeted quantitative PCR (Folate-LT qPCR) method for the selective detection and quantification of FR+ CTCs in gastric cancer patients.
FASEB J
July 2025
Victor Chang Cardiac Research Institute, Sydney, New South Wales, Australia.
Nicotinamide adenine dinucleotide (NAD) is an essential cofactor in hundreds of cellular processes. Genetic disruption of NAD de novo synthesis causes congenital NAD deficiency disorder (CNDD), characterized by multiple congenital malformations or death in utero. Patient outcomes are highly variable, likely due to differences in the availability of maternal NAD precursors vitamin B3 and tryptophan to the embryo and its extraembryonic tissues.
View Article and Find Full Text PDFEur J Cancer
August 2025
Department of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.
Introduction: We investigated the role of integrating tissue biopsy (TBx)- and liquid biopsy (LBx)-comprehensive genomic profiling (CGP) to predict the activity of FOLFIRI plus cetuximab.
Methods: The CAPRI-2 GOIM study is a non-randomized phase 2 study evaluating a biomarker-driven anti-EGFR treatment in three lines of therapy in patients with RAS/BRAF wild type metastatic colorectal cancer. At baseline, TBx and LBx were analyzed using the FoundationOne CDx platform.
BMC Med
July 2025
General Surgery Department, Dongcheng District, Peking Union Medical College Hospital, No. 1 Shuaifuyuan, Beijing, 100730, China.
Background: This study assessed the safety, preliminary antitumor activity, and pharmacokinetics of HR070803 (a novel liposomal irinotecan) in combination with 5-FU/LV and oxaliplatin for treatment-naive patients with unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).
Methods: This multicenter, open-label, single-arm, dose-escalation phase 1 study recruited treatment-naive patients aged 18-70 years with unresectable locally advanced or metastatic PDAC. Treatment doses were escalated from 40/60 (HR070803 40 mg/m plus 5-FU/LV and oxaliplatin 60 mg/m) to 60/60 and 60/85.